Tissue of Origin Test – Pathwork Diagnostics

It can be challenging to accurately diagnose the tissue of origin in metastatic, poorly differentiated, and undifferentiated tumors, even after imaging and extensive histological workup.  There is an increased need for high confidence tissue of origin diagnosis driven by the opportunity to prescribe more effective, less toxic, targeted therapies. Pathwork Diagnostics recently launched a new molecular test, the Tissue of Origin Test, that utilizes gene expression profiling to assist in the diagnosis of tissue of origin. Pathwork’s Tissue of Origin Test is extremely accurate, has been extensively validated in peer-reviewed publications, and should be used to complement traditional histological work-up in difficult to diagnose cases where there is uncertainty regarding the diagnosis. More information on the test, including soft copies of publications, is available at www.pathworkdx.com

At AstraZeneca, we believe it's not enough for us to simply make medicines. We have to make sure that the people who need those medicines can get them. It's why we've offered patient assistance programs for over 30 years.

Since 1978, we've worked hard to better understand the needs of patients and the healthcare system so that our patient assistance programs can make a difference. In 2008, AstraZeneca helped over 440,000 people fill
2.7 million prescriptions resulting in more than $600 million of savings to patients.

Our commitment to improving health isn't just through our innovations in the lab; it's also through knowing the people who use our medicines and helping them get these medicines when they need them."

Is this what you had in mind?  Thanks for letting me know you received the check!  Hope to see you in '10!  Joan